MCID: ULC008
MIFTS: 22

Ulcerative Proctitis malady

Categories: Rare diseases, Gastrointestinal diseases

Aliases & Classifications for Ulcerative Proctitis

Aliases & Descriptions for Ulcerative Proctitis:

Name: Ulcerative Proctitis 50
Chronic Ulcerative Proctitis 69

Classifications:



External Ids:

ICD10 33 K51.2

Summaries for Ulcerative Proctitis

NIH Rare Diseases : 50 ulcerative proctitis is a type of ulcerative colitis that affects the rectum. the symptoms of this form of proctitis may include bleeding from the rectum, the need to go to the bathroom frequently, tenesmus, diarrhea or constipation, and rectal pain. people with ulcerative proctitis tend to have episodes when the symptoms worsen and periods without symptoms, although the course of the disease varies among affected individuals. treatment involves applying 5-aminosalicylic acid (5-asa) or steroid creams to the rectum. in some cases, an oral version of 5-asa is used to prevent episodes. last updated: 12/11/2012

MalaCards based summary : Ulcerative Proctitis, also known as chronic ulcerative proctitis, is related to proctitis and colitis. An important gene associated with Ulcerative Proctitis is CRP (C-Reactive Protein). The drugs Tacrolimus and Sucralfate have been mentioned in the context of this disorder. Affiliated tissues include monocytes.

Related Diseases for Ulcerative Proctitis

Diseases related to Ulcerative Proctitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
id Related Disease Score Top Affiliating Genes
1 proctitis 10.7
2 colitis 10.2
3 ulcerative colitis 10.1
4 constipation 9.7
5 intestinal pseudo-obstruction 9.7
6 lupus erythematosus 9.7
7 rectal prolapse 9.7
8 lymphomatoid papulosis 9.7
9 systemic lupus erythematosus 9.7
10 cytomegalovirus infection 9.7
11 crohn's disease 9.7
12 hemolytic anemia 9.7
13 neutropenia 9.7
14 inflammatory bowel disease 9.7
15 mucositis 9.7
16 lymphogranuloma venereum 9.7
17 pericarditis 9.7

Graphical network of the top 20 diseases related to Ulcerative Proctitis:



Diseases related to Ulcerative Proctitis

Symptoms & Phenotypes for Ulcerative Proctitis

Drugs & Therapeutics for Ulcerative Proctitis

Drugs for Ulcerative Proctitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
2
Sucralfate Approved Phase 4 54182-58-0
3 Gastrointestinal Agents Phase 4,Phase 2
4 Antacids Phase 4
5 Immunosuppressive Agents Phase 4,Phase 2
6 Anti-Ulcer Agents Phase 4
7 Calcineurin Inhibitors Phase 4,Phase 2
8
Budesonide Approved Phase 3,Phase 2 51333-22-3 63006 5281004
9 Mesalamine Phase 3,Phase 2 89-57-6
10 Analgesics Phase 3,Phase 2
11 glucocorticoids Phase 3,Phase 2
12 Analgesics, Non-Narcotic Phase 3,Phase 2
13 Hormone Antagonists Phase 3,Phase 2
14 Hormones Phase 3,Phase 2
15 Peripheral Nervous System Agents Phase 3,Phase 2
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
17 Anti-Asthmatic Agents Phase 3,Phase 2
18 Anti-Inflammatory Agents Phase 3,Phase 2
19 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2
20 Respiratory System Agents Phase 3,Phase 2
21 Antirheumatic Agents Phase 3,Phase 2
22 Autonomic Agents Phase 3,Phase 2
23 Bronchodilator Agents Phase 3,Phase 2
24 Cola Nutraceutical Phase 3,Phase 2
25
Midazolam Approved, Illicit Phase 2 59467-70-8 4192
26
Propofol Approved, Investigational, Vet_approved Phase 2 2078-54-8 4943
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2 437-38-7 3345
28
Bisacodyl Approved Phase 2 603-50-9
29 Orange Nutraceutical Phase 2

Interventional clinical trials:

(show all 16)
id Name Status NCT ID Phase
1 Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4
2 Combined Therapy in Radiation Proctopathy Completed NCT01613534 Phase 4
3 The Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis Completed NCT01349673 Phase 3
4 Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Completed NCT01008423 Phase 3
5 Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis Completed NCT01008410 Phase 3
6 Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis Terminated NCT01016262 Phase 3
7 Clinical Trial With Mesalamine 1g Suppositories Terminated NCT01172444 Phase 3
8 Safety, Tolerability, Biomarker and Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis Unknown status NCT01149707 Phase 2
9 Assessment of Photopill Capsule Treatment for Safety and Feasibility in Ulcerative Proctitis Completed NCT01837615 Phase 2
10 Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis Completed NCT01966783 Phase 2
11 Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial. Completed NCT02104271 Phase 2
12 Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome Withdrawn NCT00514982 Phase 2
13 Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease Completed NCT02025777
14 Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treatment Completed NCT01684514
15 Phenomics in Autoimmune and Inflammatory Diseases Recruiting NCT02466217
16 QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®) Active, not recruiting NCT02368743

Search NIH Clinical Center for Ulcerative Proctitis

Genetic Tests for Ulcerative Proctitis

Anatomical Context for Ulcerative Proctitis

MalaCards organs/tissues related to Ulcerative Proctitis:

39
Monocytes

Publications for Ulcerative Proctitis

Articles related to Ulcerative Proctitis:

(show top 50) (show all 102)
id Title Authors Year
1
Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. ( 28089625 )
2016
2
Clinical pattern and progression of ulcerative proctitis in the Japanese population: a retrospective study of incidence and risk factors influencing progression. ( 26663677 )
2016
3
Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. ( 27489240 )
2016
4
Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. ( 27446860 )
2016
5
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. ( 27416045 )
2016
6
P587. Tacrolimus suppositories in therapy-resistant ulcerative proctitis - a single center experience. ( 25718087 )
2015
7
P461. Therapeutic requirements and health resources in the treatment of clinically active ulcerative proctitis. ( 25717954 )
2015
8
Improvement of Refractory Ulcerative Proctitis With Sacral Nerve Stimulation. ( 25930972 )
2015
9
A case of appendectomy as main therapeutic intervention for complex co-morbid ulcerative proctitis. ( 25690705 )
2015
10
P214. Ulcerative Proctitis: Predictors and outcomes of disease extension in UC. ( 25717682 )
2015
11
Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. ( 25644096 )
2015
12
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. ( 26386854 )
2015
13
Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis. ( 25687266 )
2015
14
Oral 5-aminosalicylate, mesalamine suppository and mesalamine enema as initial therapy for ulcerative proctitis in clinical practice with quality of care implications. ( 26469062 )
2015
15
Gastrointestinal symptoms resembling ulcerative proctitis caused by larvae of the drone fly Eristalis tenax. ( 24766340 )
2014
16
Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine. ( 26185880 )
2014
17
Ulcerative proctitis: an update on the pharmacotherapy and management. ( 24837209 )
2014
18
Drug Therapies for Ulcerative Proctitis: Systematic Review and Meta-analysis. ( 25072502 )
2014
19
Proximal disease extension and related predicting factors in ulcerative proctitis. ( 24325564 )
2014
20
Ulcerative proctitis in out-patient practice: an unexpected clinical challenge. ( 25176055 )
2014
21
Comparison of Xilei-san, a Chinese herbal medicine, and dexamethasone in mild/moderate ulcerative proctitis: a double-blind randomized clinical trial. ( 23383973 )
2013
22
Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued? ( 23576086 )
2012
23
Psoriatic colitis mimicking ulcerative proctitis in an elderly patient. ( 22884084 )
2012
24
Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study. ( 22690748 )
2012
25
Expanding the therapeutic armamentarium of ulcerative proctitis. ( 23167520 )
2012
26
A rare case of ulcerative proctitis associated with type B lymphomatoid papulosis and superimposed human cytomegalovirus infection. ( 22715829 )
2012
27
Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. ( 22775479 )
2012
28
Appendicectomy as a potential therapy for refractory ulcerative proctitis. ( 21679209 )
2011
29
A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. ( 20676771 )
2011
30
Hydrogen peroxide exposure mimicking ulcerative proctitis. ( 21130717 )
2011
31
Infliximab for refractory ulcerative proctitis. ( 20222911 )
2010
32
Recurrent pericarditis in a patient with ulcerative proctitis due to mesalazine suppositories. ( 20237787 )
2010
33
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. ( 20310020 )
2010
34
Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. ( 20848454 )
2010
35
Appendicectomy as a therapy for ulcerative proctitis. ( 19584834 )
2009
36
Topically administered infliximab can work in ulcerative proctitis despite the ineffectiveness of intravenous induction therapy. ( 19436284 )
2009
37
Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes. ( 20574506 )
2009
38
Appendiceal orifice inflammation and ulcerative proctitis. ( 18674731 )
2008
39
A combination of rectal beclomethasone diproprionate and mesalazine in ulcerative proctitis. ( 18415762 )
2008
40
Ulcerative proctitis: a review of pharmacotherapy and management. ( 18345952 )
2008
41
Rectal tacrolimus in the treatment of resistant ulcerative proctitis. ( 18761706 )
2008
42
A suppository Chinese medicine (xilei-san) for refractory ulcerative proctitis: a pilot clinical trial. ( 17675886 )
2007
43
Colorectal motor and sensitivity features in patients affected by ulcerative proctitis with constipation: a radiological and manometric controlled study. ( 16917226 )
2006
44
Ulcerative proctitis in men who have sex with men: an emerging outbreak. ( 16410585 )
2006
45
Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. ( 17012968 )
2006
46
Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. ( 16393311 )
2006
47
Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. ( 17012969 )
2006
48
Treatment of refractory ulcerative proctitis with argon plasma coagulation: case report. ( 15278074 )
2004
49
Granulocyte, macrophage, monocyte apheresis for refractory ulcerative proctitis. ( 15316424 )
2004
50
Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. ( 15626890 )
2004

Variations for Ulcerative Proctitis

Expression for Ulcerative Proctitis

Search GEO for disease gene expression data for Ulcerative Proctitis.

Pathways for Ulcerative Proctitis

GO Terms for Ulcerative Proctitis

Sources for Ulcerative Proctitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....